Work

Accelerating Medicines Partnership - Schizophrenia (AMP SCZ) Data Repository

Year: 2025

Type: data-paper

Abstract: The National Institutes of Health (NIH) is launching a new public-private partnership to accelerate the development of promising therapies for those at risk of developing schizophrenia (SCZ). Part of the Accelerating Medicines Partnership (AMP), AMP SCZ brings together NIH, the U.S. Food and Drug Administration (FDA), and multiple biopharmaceutical, life science, academic, and not-for-profit organizations with the shared goal of discovering better ways of identifying and treating those at clinical high risk for psychosis. The National Institute of Mental Health (NIMH) joins fellow NIH Institutes supporting AMP programs. AMP SCZ adds to ongoing NIMH efforts focused on early detection and intervention in SCZ.

Source: National Institutes of Health, National Institute of Mental Health (NIMH) Data Archive Repository

DOI: 10.15154/81xe-k706

Authors: Asgari-Targhi, Ameneh, Nelson B; McGorry P; Woods S; Bearden C; Kane J; Shenton M; Kahn R

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6923612882

Cites:

Cited by:

Related to: